
News|Articles|February 1, 2012
FDA Pipeline Preview, February 2012 (Bristol-Myers Squibb, AstraZeneca, Columbia Laboratories, Watson Pharmaceuticals, Achillion, Catalyst Pharmaceutical Partners, AlloCure, Neurocrine Biosciences, AiCuris, CanBas, Pinnacle Biologics, Ikaria)
Recent FDA action (through January 2012) related to dapagliflozin, progesterone vaginal gel 8%, ACH-1625 protease inhibitor, CPP-115 GABA aminotransferase inhibitor, AC607, NBI-98854 VMAT2 inhibitor, AIC246 inhibitor, CBP501, Porfimer sodium, inhaled nitric oxide, carbamazepine extended-release capsules, levetiracetam extended-release tablets
Advertisement
Complete response
Not recommended forapproval
Orphan drug designations
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Medicare Part D redesign reshapes market
2
A conversation with Tiffany Phung, Pharm.D., CSP, about how patient outcomes drive specialty pharmacy strategy
3
The sleep doctor who lives with a disorder he treats
4
Managing Chronic Disease Shouldn't Feel Like a Full-Time Job
5




















